A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

This study contains two parts: Part 1 and Part 2. Part 1 (24-Week Placebo-controlled Period): Eligible patients will be randomized in a 1:1:1:1 ratio to receive either camoteskimab dose 1, camoteskimab dose 2, camoteskimab dose 3 or placebo. Part 2 (Extension Period): In part 2, all participants will receive camoteskimab. This study will enroll both treatment-naive participants and those with an inadequate response to previous biologic therapy.